Suzanne Staples

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez et al. · The Lancet Respiratory Medicine · 2019 · 161 citations · Full text

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 143 citations · Full text

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Conor Tweed, Genevieve H. Wills, Angela M. Crook et al. · The International Journal of Tuberculosis and Lung Disease · 2021 · 61 citations · Full text

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Müge Çevik, Lindsay C Thompson, Caryn M. Upton et al. · The Lancet Infectious Diseases · 2024 · 47 citations · Full text

Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis

Anneke C Hesseling, Susan E. Purchase, Neil Martinson et al. · New England Journal of Medicine · 2024 · 44 citations